Results 121 to 130 of about 4,268 (199)

Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover Study. [PDF]

Adv Ther
Elliot ER, Boles J, Fox D, Nelson KL, Dupont-Benjamin L, Vutikullird A, Mottola A, Fletcher K, Wang K, Somvanshi S, Grove R, Strano K, Pilgrim N, Borsi R, Budnik P, van Wyk J, Garges HP, Brown K.   +17 more
europepmc   +1 more source

Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study. [PDF]

Open Forum Infect Dis
Córdova E, Rolle CP, Hove K, Felizarta F, Johnson M, Cuevas Tascón G, Molina JM, Bravo Urbieta J, Hocqueloux L, Lupo S, Perez CM, Ole Jensen BE, Jonsson-Oldenbüttel C, Zamora Vargas FX, Szabo J, Cahn P, Antinori A, López Bernaldo de Quirós JC, Castagna A, Bui M, Grove R, Wang K, St Clair M, Moodley R, Radford J, Priest J, Gutner CA, Jacob I, Chatterjee A, Somvanshi S, Kolobova I, Trehan R, Polk C, Patel P, de Los Rios P, DiMondi P, Gordon LA, Brown K, Garges HP, Jones B, van Wyk J.   +40 more
europepmc   +1 more source

Combined injectable regimens in treatment-experienced HIV/AIDS patients at a southern academic medical center: a case series. [PDF]

BMC Infect Dis
Burton HJ, Rivere E, Kirk S, Berry H, Lueking R.   +4 more
europepmc   +1 more source

Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan. [PDF]

Adv Ther
Yoshikawa Y, Nagao T, Matsukawa T, Maeno Y, Sebata A, Suzuki M, Ibe S, Fukuda A, Wang D.   +8 more
europepmc   +1 more source

Epidemiologic Impact of Prioritizing Long-Acting Injectable Cabotegravir to Men Who Have Sex With Men With Low Pre-Exposure Prophylaxis Use Adherence in the Netherlands: A Mathematical Modeling Study. [PDF]

J Acquir Immune Defic Syndr
Wang H, Jonas KJ, van de Vijver D.
europepmc   +1 more source

Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa. [PDF]

Nat Commun
Phillips A, Smith J, Bansi-Matharu L, Sikwese K, Kityo C, Flexner C, Vitoria M, Ford N, Doherty M, Panos Z, Ripin D, Hickey M, Havlir D, Gandhi M, Reid M, Revill P.   +15 more
europepmc   +1 more source

Implementation of Long-Acting Cabotegravir/Rilpivirine in US HIV Care Settings: Results From a National Survey of Frontline Clinicians. [PDF]

Open Forum Infect Dis
Short WR, Ogle MC, Farmer E, Kapalko A, Packett B, Riley AC, Binkley A.   +6 more
europepmc   +1 more source

Long-Acting Antiretroviral Therapy for HIV via Drop-in Community-Based Care.

JAMA Netw Open
Mehtani NJ, Matzat SJ, O'Connor KB, Cordoba L, Strieff S, Strough A, Philbin MM, Johnson MO, Gandhi M, Zevin B.   +9 more
europepmc   +1 more source

Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP? [PDF]

J Acquir Immune Defic Syndr
D'Angelo AB, Patel VV, Carrico AW, Grov C.   +3 more
europepmc   +1 more source

Efficacy of Long-Acting Injectable Cabotegravir and Rilpivirine Compared With Daily Oral Antiretroviral Therapy in Patients With HIV: A Systematic Review. [PDF]

Cureus
Endara-Mina J, Quishpe M, Vera E, Haro N, Guzmán A, Guillin J, Quisnancela K, Sarmiento-Vallejo H, Mantilla-Alcivar I, Cabrera C, Cueva J, Serrano S, Caiza C, Intriago C, Salazar P.   +14 more
europepmc   +1 more source